<p>擁有大量資金的投資者對 <strong>Abivax</strong> (NASDAQ: ABVX) 持悲觀態度。</p>
<p>而散户交易者應該知道這一點。</p>
<p>我們今天注意到這一點，因為這些頭寸出現在我們在 Benzinga 跟蹤的公開可用期權歷史中。</p>
<p>我們不知道這些是機構還是僅僅是富有的個人。但當 ABVX 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
<p>今天，Benzinga 的期權掃描儀發現了 12 筆 <strong>Abivax</strong> 的期權交易。</p>
<p>這並不正常。</p>
<p>這些大資金交易者的整體情緒在 41% 看漲和 50% 看跌之間分裂。</p>
<p>在我們發現的所有期權中，有 1 筆看跌期權，總金額為 $31,360，和 11 筆看漲期權，總金額為 $605,529。</p>
<h3>預期價格變動</h3>
<p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注的價格區間為 $90.0 到 $175.0。</p>
<h3>成交量與未平倉合約趨勢</h3>
<p>查看成交量和未平倉合約是交易期權時的一個強有力的舉措。這些數據可以幫助你跟蹤 Abivax 在特定行權價的期權流動性和興趣。下面，我們可以觀察到在過去 30 天內，所有 Abivax 的鯨魚交易在 $90.0 到 $175.0 的行權價範圍內的成交量和未平倉合約的演變。</p>
<h3>Abivax 30 天期權成交量與興趣快照</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768413676_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768413676_0.png"/></p>
<h3>發現的最大期權：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$125.00</td>
<td>$147.9K</td>
<td>533</td>
<td align="right">292</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>02/20/26</td>
<td>$17.0</td>
<td>$13.5</td>
<td>$15.0</td>
<td>$130.00</td>
<td>$108.0K</td>
<td>465</td>
<td align="right">100</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$11.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>1.9K</td>
<td align="right">216</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$28.9</td>
<td>$25.5</td>
<td>$26.63</td>
<td>$110.00</td>
<td>$39.9K</td>
<td>10</td>
<td align="right">15</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$13.4</td>
<td>$14.9</td>
<td>$110.00</td>
<td>$37.2K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
</tbody>
</table>
<h3>關於 Abivax</h3>
<p>Abivax SA 是一家總部位於法國的臨牀階段生物技術公司，專注於開發利用身體自然調節機制的治療方法，以穩定慢性炎症性疾病患者的免疫反應。該公司正在評估其藥物候選者 obefazimod，在 3 期臨牀試驗中用於治療中度至重度活動性潰瘍性結腸炎的成年人。其初步關注的是炎症性腸病，這是一種涉及胃腸道炎症的慢性疾病，其中兩種常見形式為 UC 和 CD。</p>
<p>鑑於 Abivax 最近的期權歷史，現在適合關注該公司本身。我們旨在探討其當前表現。</p>
<h3>Abivax 的當前狀況</h3>
<ul>
<li>目前交易量為 1,013,271，ABVX 的價格上漲了 1.32%，現為 $121.22。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計收益發布將在 68 天后。</li>
</ul>
<h3>專家對 Abivax 的看法</h3>
<p>在過去 30 天內，共有 3 位專業分析師對該股票發表了看法，設定的平均目標價為 $142.0。</p>
<ul>
<li>一位來自 Citizens 的分析師維持對 Abivax 的市場表現優於大盤評級，目標價為 $131。</li>
<li>一位來自 BTIG 的分析師繼續對 Abivax 維持買入評級，目標價為 $150。</li>
<li>一位來自摩根士丹利的分析師決定維持對 Abivax 的增持評級，目前目標價為 $145。</li>
</ul>
<p>交易期權涉及更大的風險，但也提供了更高的利潤潛力。精明的交易者通過持續教育、戰略性交易調整、利用各種指標以及關注市場動態來降低這些風險。</p>

ABVX

<p>投資者對 Abivax (NASDAQ:ABVX) 持悲觀態度，50% 的大額交易者表現出看跌情緒。最近的期權活動顯示出 12 筆交易，其中包括 1 筆價值 31,360 美元的看跌期權和 11 筆總計 605,529 美元的看漲期權。Abivax 的預期價格區間在 90.0 美元到 175.0 美元之間。目前，ABVX 的交易價格為 121.22 美元，上漲 1.32%。分析師設定的平均目標價為 142.0 美元，評級範圍從市場跑贏到買入，儘管期權情緒悲觀，但仍顯示出增長潛力</p>

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Abivax</strong> (NASDAQ: ABVX).</p>
<div class="lb-trans"><p>擁有大量資金的投資者對 <strong>Abivax</strong> (NASDAQ: ABVX) 持悲觀態度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者應該知道這一點。</p>
</div><p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我們今天注意到這一點，因為這些頭寸出現在我們在 Benzinga 跟蹤的公開可用期權歷史中。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABVX, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>我們不知道這些是機構還是僅僅是富有的個人。但當 ABVX 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
</div><p>Today, Benzinga's options scanner spotted 12 options trades for <strong>Abivax</strong>.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描儀發現了 12 筆 <strong>Abivax</strong> 的期權交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>這並不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 41% bullish and 50%, bearish.</p>
<div class="lb-trans"><p>這些大資金交易者的整體情緒在 41% 看漲和 50% 看跌之間分裂。</p>
</div><p>Out of all of the options we uncovered, there was 1 put, for a total amount of $31,360, and 11, calls, for a total amount of $605,529.</p>
<div class="lb-trans"><p>在我們發現的所有期權中，有 1 筆看跌期權，總金額為 $31,360，和 11 筆看漲期權，總金額為 $605,529。</p>
</div><h3>Expected Price Movements</h3>
<div class="lb-trans"><h3>預期價格變動</h3>
</div><p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $175.0 for Abivax during the past quarter.</p>
<div class="lb-trans"><p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注的價格區間為 $90.0 到 $175.0。</p>
</div><h3>Volume &amp; Open Interest Trends</h3>
<div class="lb-trans"><h3>成交量與未平倉合約趨勢</h3>
</div><p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Abivax's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abivax's whale trades within a strike price range from $90.0 to $175.0 in the last 30 days.</p>
<div class="lb-trans"><p>查看成交量和未平倉合約是交易期權時的一個強有力的舉措。這些數據可以幫助你跟蹤 Abivax 在特定行權價的期權流動性和興趣。下面，我們可以觀察到在過去 30 天內，所有 Abivax 的鯨魚交易在 $90.0 到 $175.0 的行權價範圍內的成交量和未平倉合約的演變。</p>
</div><h3>Abivax 30-Day Option Volume &amp; Interest Snapshot</h3>
<div class="lb-trans"><h3>Abivax 30 天期權成交量與興趣快照</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768413676_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2026/1768413676_0.png"/></p>
<h3>Biggest Options Spotted:</h3>
<div class="lb-trans"><h3>發現的最大期權：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$125.00</td>
<td>$147.9K</td>
<td>533</td>
<td align="right">292</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/20/26</td>
<td>$17.0</td>
<td>$13.5</td>
<td>$15.0</td>
<td>$130.00</td>
<td>$108.0K</td>
<td>465</td>
<td align="right">100</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$11.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>1.9K</td>
<td align="right">216</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$28.9</td>
<td>$25.5</td>
<td>$26.63</td>
<td>$110.00</td>
<td>$39.9K</td>
<td>10</td>
<td align="right">15</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$13.4</td>
<td>$14.9</td>
<td>$110.00</td>
<td>$37.2K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$125.00</td>
<td>$147.9K</td>
<td>533</td>
<td align="right">292</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>02/20/26</td>
<td>$17.0</td>
<td>$13.5</td>
<td>$15.0</td>
<td>$130.00</td>
<td>$108.0K</td>
<td>465</td>
<td align="right">100</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$11.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>1.9K</td>
<td align="right">216</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$28.9</td>
<td>$25.5</td>
<td>$26.63</td>
<td>$110.00</td>
<td>$39.9K</td>
<td>10</td>
<td align="right">15</td>
</tr>
<tr>
<td>ABVX</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$13.4</td>
<td>$14.9</td>
<td>$110.00</td>
<td>$37.2K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
</tbody>
</table>
</div><h3>About Abivax</h3>
<div class="lb-trans"><h3>關於 Abivax</h3>
</div><p>Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.</p>
<div class="lb-trans"><p>Abivax SA 是一家總部位於法國的臨牀階段生物技術公司，專注於開發利用身體自然調節機制的治療方法，以穩定慢性炎症性疾病患者的免疫反應。該公司正在評估其藥物候選者 obefazimod，在 3 期臨牀試驗中用於治療中度至重度活動性潰瘍性結腸炎的成年人。其初步關注的是炎症性腸病，這是一種涉及胃腸道炎症的慢性疾病，其中兩種常見形式為 UC 和 CD。</p>
</div><p>In light of the recent options history for Abivax, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<div class="lb-trans"><p>鑑於 Abivax 最近的期權歷史，現在適合關注該公司本身。我們旨在探討其當前表現。</p>
</div><h3>Current Position of Abivax</h3>
<div class="lb-trans"><h3>Abivax 的當前狀況</h3>
</div><ul>
<li>Currently trading with a volume of 1,013,271, the ABVX's price is up by 1.32%, now at $121.22.</li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量為 1,013,271，ABVX 的價格上漲了 1.32%，現為 $121.22。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計收益發布將在 68 天后。</li>
</ul>
</div><h3>Expert Opinions on Abivax</h3>
<div class="lb-trans"><h3>專家對 Abivax 的看法</h3>
</div><p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $142.0.</p>
<div class="lb-trans"><p>在過去 30 天內，共有 3 位專業分析師對該股票發表了看法，設定的平均目標價為 $142.0。</p>
</div><ul>
<li>Maintaining their stance, an analyst from Citizens continues to hold a Market Outperform rating for Abivax, targeting a price of $131.</li>
<li>An analyst from BTIG persists with their Buy rating on Abivax, maintaining a target price of $150.</li>
<li>An analyst from Morgan Stanley has decided to maintain their Overweight rating on Abivax, which currently sits at a price target of $145.</li>
</ul>
<div class="lb-trans"><ul>
<li>一位來自 Citizens 的分析師維持對 Abivax 的市場表現優於大盤評級，目標價為 $131。</li>
<li>一位來自 BTIG 的分析師繼續對 Abivax 維持買入評級，目標價為 $150。</li>
<li>一位來自摩根士丹利的分析師決定維持對 Abivax 的增持評級，目前目標價為 $145。</li>
</ul>
</div><p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics.</p>
<div class="lb-trans"><p>交易期權涉及更大的風險，但也提供了更高的利潤潛力。精明的交易者通過持續教育、戰略性交易調整、利用各種指標以及關注市場動態來降低這些風險。</p>
</div>

Abivax 的選擇：探討大資金的想法